Simulations Plus SLP recently announced the acquisition of Pro-ficiency Holdings, Inc. and its subsidiaries from QHP Capital and its minority shareholders. The company specializes in offering ...

Another key platform, GastroPlus, is a physiologically based pharmacokinetic modeling system used to simulate drug absorption and systemic exposure. These platforms support drug development programs ...

Simulations Plus is benefiting from the growing use of computational tools in drug discovery, which would be boosted by the FDA Modernization Act 2.0. The biosimulation market is highly fragmented and ...

Simulations Plus, Inc. has seen stagnant stock trading despite impressive growth in the biosimulation market. Recent margin pressure and M&A activity raise concerns about management's ability to ...

Simulations Plus is a software company that develops tools for modeling and simulation in the pharmaceutical, biotechnology, and chemical industries. In June 2024, Simulations Plus acquired ...

Simulations Plus (NASDAQ:SLP) offers advanced modeling software for the pharmaceutical and biotechnology industries within nasdaq today.

Simulations Plus (SLP) shares ended the last trading session 8.9% higher at $30.04. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Image source: The Motley Fool. Need a quote from one of our analysts? Email pr@fool.com Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. A $77.2 ...

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods ...